home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2795.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
38 lines
Document 2795
DOCN M94A2795
TI DHEA: a potential treatment for HIV disease.
DT 9412
AU Hasheeve D; Salvato P; Thompson C; Houston Immuno. Institute, TX.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):223 (abstract no. PB0322). Unique
Identifier : AIDSLINE ICA10/94369780
AB OBJECTIVE: To evaluate the use of Dehydroepiandrosterone (DHEA), a
testosterone precursor with possible immunomodulating affects, as an
adjunct therapy for HIV disease. METHODS: 12 pts. with AIDS were treated
with DHEA in addition to standard antiviral and prophylactic OI therapy
for HIV infection. (2:CD4 < 50; 6:CD4 50-100; 4:CD4 101-200). In
addition to DHEA, 4 pts. were receiving AZT/DDC, 2 were on AZT alone, 3
were on DDI alone, 1 was on AZT/DDI, and 2 were not receiving
antivirals. Pts. received an average oral DHEA dosage of 75 mg qd.
CD4/CD8 counts were obtained at baseline and at one month intervals.
Pts. were followed from 4 to 12 months with a mean of 8 months. RESULTS:
2 pts. were deceased at the end of 12 months. 9 of the remaining 10 pts.
demonstrated an increase in CD4 count. 5 of the 9 (56%) demonstrated a >
25% increase in CD4 count. 8 pts. (68%) experienced an increase in CD8
count; 2 (17%) demonstrated a > 25% increase in CD8 count. CONCLUSIONS:
The majority of pts. on DHEA adjunct therapy experienced an increase in
both CD4 and CD8 counts. A > 25% increase in CD4 count is clinically
significant. How this increase relates to survival is unknown. Some
reports equate increase in CD8 counts with long term survival. A
randomized clinical trial of this drug appears warranted.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY/*THERAPY Adjuvants,
Immunologic/*THERAPEUTIC USE Anti-Infective Agents/THERAPEUTIC USE
Antiviral Agents/THERAPEUTIC USE Combined Modality Therapy
Didanosine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Drug Evaluation
Drug Therapy, Combination Human Leukocyte Count/DRUG EFFECTS
Prasterone/*THERAPEUTIC USE Treatment Outcome T4 Lymphocytes
Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).